Position of the MPA regarding Lucentis and Avastin

Lucentis (ranibizumab) is approved for the treatment of neovascular age related macular degeneration (AMD), for the treatment of visual impairment due to diabetic macular oedema (DME) and retinal vein occlusions (RVO).

Source: MPA RSS news - - March 16, 2012 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news